SUVOREXANT Dual Orexin OX1/OX2 Receptor Antagonist Treatment of Sleep Disorders

被引：2
|
作者：
Radl, S. [1 ]
机构：
[1] Zentiva, Prague 10237, Czech Republic
来源：
DRUGS OF THE FUTURE | 2013年 / 38卷 / 01期
关键词：
Orexin receptor antagonist; Insomnia; Sleep apnea; Suvorexant; MK-4305; PHARMACOLOGY; DISCOVERY; AMINATION;
D O I：
10.1358/dof.2013.038.01.1906425
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Suvorexant is a novel, selective, orally active dual orexin OX1 and OX2 receptor antagonist under development by Merck & Co. Phase Ill clinical trials for the treatment of insomnia have been completed and phase I clinical trials for the treatment of sleep apnea are under way. The phase III results suggested that patients taking suvorexant fell asleep faster and slept longer than those on placebo.
引用
收藏
页码：27 / 36
页数：10
相关论文
共 50 条
  • [1] Daridorexant Dual orexin OX1/OX2 receptor antagonist Treatment of sleep disorders
    Gras, J.
    DRUGS OF THE FUTURE, 2020, 45 (10) : 707 - 716
  • [2] ALMOREXANT Dual Orexin OX1/OX2 Antagonist Treatment of Sleep Disorders
    Owen, R. T.
    Castaner, R.
    Bolos, J.
    Estivill, C.
    DRUGS OF THE FUTURE, 2009, 34 (01) : 5 - 10
  • [3] Biochemical and Electrophysiological Characterization of Almorexant, a Dual Orexin 1 Receptor (OX1)/Orexin 2 Receptor (OX2) Antagonist: Comparison with Selective OX1 and OX2 Antagonists
    Malherbe, Pari
    Borroni, Edilio
    Pinard, Emmanuel
    Wettstein, Joseph G.
    Knoflach, Frederic
    MOLECULAR PHARMACOLOGY, 2009, 76 (03) : 618 - 631
  • [4] OX1 and OX2 orexin/hypocretin receptor pharmacogenetics
    Thompson, Miles D.
    Xhaard, Henri
    Sakurai, Takeshi
    Rainero, Innocenzo
    Kukkonen, Jyrki P.
    FRONTIERS IN NEUROSCIENCE, 2014, 8
  • [5] Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands
    Turku, Ainoleena
    Borrel, Alexandre
    Leino, Teppo O.
    Karhu, Lasse
    Kukkonen, Jyrki P.
    Xhaard, Henri
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (18) : 8263 - 8275
  • [6] Opposite effects of sleep rebound on orexin OX1 and OX2 receptor expression in rat brain
    D'Almeida, V
    Hipólide, DC
    Raymond, R
    Barlow, KBL
    Parkes, JH
    Pedrazzoli, M
    Tufik, S
    Nobrega, JN
    MOLECULAR BRAIN RESEARCH, 2005, 136 (1-2): : 148 - 157
  • [7] Distinct recognition of OX1 and OX2 receptors by orexin peptides
    Ammoun, S
    Holmqvist, T
    Shariatmadari, R
    Oonk, HB
    Detheux, M
    Parmentier, M
    Åkerman, KEO
    Kukkonen, JP
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (02): : 507 - 514
  • [8] Prepro-orexin, OX1 and OX2 receptor gene expression in rat tissues
    Jöhren, O
    Kummer, M
    Neidert, S
    Dominiak, P
    JOURNAL OF HYPERTENSION, 2000, 18 : S141 - S141
  • [9] A comparison of the distribution of orexin A and the orexin receptors, OX1 and OX2, in lean and obese Zucker rats
    Bewick, GA
    Smith, SL
    Viggers, JA
    Guerin, CJ
    Heal, DJ
    Cheetham, SC
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 : U81 - U81
  • [10] Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists
    Faedo, Stefania
    Perdona, Elisabetta
    Antolini, Marinella
    di Fabio, Romano
    Pich, Emilio Merlo
    Corsi, Mauro
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 692 (1-3) : 1 - 9
12345